Press Release Details

Adicet Bio to Present at J.P. Morgan Healthcare Conference on January 9

January 7, 2019 at 7:00 AM EST

MENLO PARK, Calif., Jan. 7, 2019 – Adicet Bio, Inc., a biopharmaceutical company focused on the development of next-generation immunotherapies, announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference.

Donald Santel, Executive Chairman of Adicet Bio, will provide a company overview on Wednesday, January 9, 2019, at 2:00pm PT.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a privately held, pre-clinical stage biotechnology company engaged in the design and development of cutting-edge immunotherapies with initial focus on cancer. Adicet is developing novel universal immune cell therapies based on gamma delta T cells engineered with Chimeric Antigen Receptors (CARs) or T Cell Receptors (TCRs). dicet is also focused on identifying and validating cancer specific targets directed to the intracellular proteome and generating TCR-like MAbs (TCRLs) directed to these cancer-specific peptide targets presented by MHC Class I complexes. These TCRLs can be used to arm T cells, as T cell engagers or as Antibody Drug Conjugates (ADC). In August 2016, Adicet entered a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics using Adicet's gamma delta T cell allogeneic platform technology. Adicet Bio raised $51M in series A financing led by OrbiMed Partners, OrbiMed Israel, Novartis Venture Fund and Pontifax. Adicet Bio is located in Menlo Park, California.

For more information, please visit our website at


Brian Hogan
Chief Financial Officer

Anne Bowdidge
Investor Relations